Literature DB >> 15757803

Molecular mechanisms in hepatocellular carcinoma development.

Charles Cha1, Ronald P Dematteo.   

Abstract

Hepatocellular carcinoma (HCC) is one of the most common cancers in the world. It usually develops in patients with chronic viral hepatitis, aflatoxin exposure, or excessive alcohol use. Most patients with HCC present with advanced disease and have a poor prognosis. The implementation of antiviral drugs and the availability of a vaccine for hepatitis B should help reduce the incidence of HCC. Considerable effort has now focused on unraveling the molecular pathogenesis of HCC in order to design better treatments, or to prevent the disease altogether. However, so far, the pathogenesis of HCC appears to be quite heterogeneous among patients. In particular, several mechanisms of tumorigenesis seem to be involved, including loss of tumor suppressor gene function, oncogene activation, direct viral effects, DNA methylation, and angiogenesis. It is not clear which events are critical in tumor initiation versus tumor progression. RNA expression arrays and proteomics hold promise to provide further clues about this common and complex cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15757803     DOI: 10.1016/j.bpg.2004.11.005

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  35 in total

Review 1.  Tumor suppressor and hepatocellular carcinoma.

Authors:  Juliette Martin; Jean-Francois Dufour
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

2.  Current imaging strategies of primary and secondary neoplasms of the liver.

Authors:  Linda Fielding
Journal:  Semin Intervent Radiol       Date:  2006-03       Impact factor: 1.513

3.  Inequality in the hepatitis B awareness level in rural residents from 7 provinces in China.

Authors:  Juan Zheng; Quan Li; Jian Wang; Guojie Zhang; Knut R Wangen
Journal:  Hum Vaccin Immunother       Date:  2017-02-14       Impact factor: 3.452

Review 4.  Chronic hepatitis B in hepatocarcinogenesis.

Authors:  N H Park; I H Song; Y-H Chung
Journal:  Postgrad Med J       Date:  2006-08       Impact factor: 2.401

5.  Molecular Pathogenesis of Hepatitis-B-virus-associated Hepatocellular Carcinoma.

Authors:  Neung Hwa Park; Il Han Song; Young-Hwa Chung
Journal:  Gut Liver       Date:  2007-12-31       Impact factor: 4.519

Review 6.  Hepatocellular carcinoma and the risk of occupational exposure.

Authors:  Venerando Rapisarda; Carla Loreto; Michele Malaguarnera; Annalisa Ardiri; Maria Proiti; Giuseppe Rigano; Evelise Frazzetto; Maria Irene Ruggeri; Giulia Malaguarnera; Nicoletta Bertino; Mariano Malaguarnera; Vito Emanuele Catania; Isidoro Di Carlo; Adriana Toro; Emanuele Bertino; Dario Mangano; Gaetano Bertino
Journal:  World J Hepatol       Date:  2016-05-08

7.  Clinical significance of hepatitis B e antigen level measurement during long-term lamivudine therapy in chronic hepatitis B patients with e antigen positive.

Authors:  Jung Woo Shin; Neung Hwa Park; Seok Won Jung; Byung Chul Kim; Sung Ho Kwon; Jae Serk Park; In Du Jeong; Sung-Jo Bang; Do Ha Kim
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

8.  Fragile histidine triad gene alterations are not essential for hepatocellular carcinoma development in South Korea.

Authors:  Chang-Woo Nam; Jung-Woo Shin; Neung-Hwa Park
Journal:  World J Gastroenterol       Date:  2008-06-14       Impact factor: 5.742

Review 9.  A niche for infectious disease in environmental health: rethinking the toxicological paradigm.

Authors:  Beth J Feingold; Leora Vegosen; Meghan Davis; Jessica Leibler; Amy Peterson; Ellen K Silbergeld
Journal:  Environ Health Perspect       Date:  2010-04-12       Impact factor: 9.031

10.  Aberrant methylation of p16 predicts candidates for 5-fluorouracil-based adjuvant therapy in gastric cancer patients.

Authors:  Mayumi Mitsuno; Yoshihiko Kitajima; Takao Ide; Kazuma Ohtaka; Masayuki Tanaka; Seiji Satoh; Kohji Miyazaki
Journal:  J Gastroenterol       Date:  2007-11-22       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.